Hinge Health Q3 2026 Earnings Call - HINGE HEALTH INC

Explicit Guidance:

• Q4 2026 Revenue: $249M–$251M (46% YoY growth at midpoint).
• Q4 2026 Operating Income: $81M–$83M (33% operating margin at midpoint).
• Full Year 2026 Revenue: Raised to $879M–$881M (50% YoY growth at midpoint, up from prior $856M–$860M).
• Full Year 2026 Operating Income: Raised to $266M–$288M (30% operating margin at midpoint).
• Full Year 2026 Yield: Expects 4.6% (up from 4.45% previously).
• Full Year 2026 Lives: Expects ~25.5M average eligible lives (LTM).
• Share Count: Q4 and Full Year 2026 diluted share count expected in 85M–87M range.
• 2027 Gross Margin Target: Targeting ~85% (down from 88% in Q3).
• 2027 ASP: Expected to remain flat year-over-year.
• 2028 ASP Outlook: Anticipates potential ASP uplift starting late 2027 into 2028 as new programs mature.

Business-Segment Outlook:

• Core MSK: Remains the primary revenue driver; estimated 88% of market lives remain untapped; expected to remain the largest contributor for years.
• Migraine Care: Early access shows 23% reduction in monthly migraine days and 28% reduction in duration; 2/3 of members improved HIT-6 scores. Expected to add 10–20 basis points to yield in 2027. Full launch targeted for early 2027 with ~8M lives and 800+ clients enrolled in early access. Long-term scale target: ~2% yield contribution per program.
• GI Care: Integrated program (AI food analysis, AI stool scan, multidisciplinary team) targeted for live in Summer 2027. Existing GI clients signed to date will upgrade upon release. Revenue contribution expected to meaningfully accelerate in 2028 after a full 2027 selling season. 20% of the migraine population and nearly 50% of the GI population also suffer from MSK pain, driving cross-sell potential.
• Hinge Select (Surgery): Strong surgeon feedback; network growing to 5,500 locations (majority PT/imaging). Launching surgical sites market-by-market; lives on Hinge Select roughly doubled since June Investor Day. Viewed as a "slower burn" but a long-term enduring model.
• SMB Segment: Added ~1M lives through Q3; sales cycles faster than enterprise with higher yields and margins; expanding sales capacity for 2027.

Market and Competitive Outlook:

• Win Rates: Trending up year-over-year; "insatiable" demand; more clients switching from competitors in 2026 than all prior years combined.
• Product Strategy: Differentiation via "multi-product adoption" and integrated care; competitors adding random conditions vs. Hinge's deliberate, unified platform approach.
• Channel Expansion: 60+ health plan, PBM, and TPA partnerships; 100% retention on health plan renewals; becoming "preferred partner" in more health plans than ever.
• SMB Penetration: Identified as highly underpenetrated; leveraging TPA/health plan opt-out/embedded models for early mover advantage.
• Pricing Model: Engagement-based billing remains central; clients value zero upfront risk and focus on ROI/clinical outcomes.

Macro / Industry Outlook:

• Employer Focus: Clients focused on driving down costs and addressing inflationary pressures; Hinge positioned as a key partner for cost containment.
• Healthcare Trends: Rising GI costs driven by GLP-1 side effects creating demand for GI care solutions.
• Open Enrollment: Similar to prior years with focus on cost reduction and comprehensive benefit packages; SMBs adopting best practices faster than enterprise.

Strategic Initiatives:

• Integrated GI Launch: Summer 2027 target for the fully unified GI care program.
• Migraine Scale-up: Bulk enrollment launch planned for early 2027 across 800+ clients.
• Hinge Select Expansion: Continued contract of surgical sites market-by-market; aiming for high-quality "precision network" rather than mass density.
• M&A Strategy: Post-M&A stance: Build organically first; use M&A only to accelerate timelines, specifically for hardware tuck-ins in MSK, GI, and migraine.
• Leadership Transition: Jim Pursley stepping down as President end of 2026 to join Board; Aaron Peer (CCO) ascending to President.
• AI & Automation: Leveraging AI across operations, care team, and member experience to maintain efficiency; 2027 gross margin target of 85% assumes continued investment in member experience and care team hiring.

Risks and Headwinds to Outlook:

• Timing Dependencies: GI and Migraine revenue impact delayed until 2028 due to integration and selling season timelines.
• Margin Cap: Gross margins expected to level off at ~85% in 2027 due to necessary care team hiring and infrastructure investments, though operating margins expected to continue improving toward 35%.
• Contracting Lag: While verbal agreements for 2027 lives are strong, final contracting occurs year-end; typical 95% conversion rate from verbal to signed applies.
• Launch Phasing: 2027 ASP is expected flat; uplift deferred to 2028 as new programs move from lower bases.

Management Tone on the Future:

• Confidence Level: "Really good about where the business is," "bullish heading into the end of 2026 and beyond," and describing the sales environment as "insatiable."
• Strategic Hedges: Emphasizes "early innings" of automation; explicitly notes 2027 is a transition year for margins (leveling gross) while building for 2028 growth.
• Differentiation: Repeatedly contrasts Hinge's deliberate, integrated platform strategy against competitors' "random condition areas."
• Long-term View: Emphasis on "free cash flow per share" over decades; goal to reach 100% of US adults with digital MSK access.

Miscellaneous:

• 2026 Selling Season: "Most under-penetrated" category (SMB) seeing substantial progress; added three new Fortune 15 clients in Q3.
• Client Renewals: Member renewals up nearly 25% YoY; referral rates up nearly triple digits YoY.
• Board Continuity: Jim Pursley remains on the Board to support the transition.
• Product Updates: "Hinge Scores" and "Movement Analysis" driving adherence; redesigned exercise experience launched Q3.